Evotec SE ranks among the weaker positions in its peer group, with a relatively even profile across the main dimensions. The market setup has weakened, with clear trend damage and relative performance under pressure. Price behavior is partially reflecting the structural picture, with a moderate gap remaining.
Discounted for Persistent Weakness, Not Missed Potential
52w drawdown -51.6% · 21d vs sector -29.4%
Peer-relative scores, weakest to strongest
Evotec SE provides drug discovery and development services to pharmaceutical partners, focusing on external collaborations and contract research.
The market prices Evotec on persistent operational weakness and peer underperformance, not on recovery expectations. With adjusted EBITDA at -€42.7M and revenue growth in Evotec Biologics down 17% year-over-year, the company’s deteriorating results and repeated guidance cuts reinforce the discount. Because Evotec, as a contract research service provider, is especially dependent on external partnerships and regulatory approvals, delays and uncertainty translate directly into negative earnings and volatile growth. As a result, the market imposes a heightened risk premium on the stock and reacts to any signs of instability by further widening the valuation discount, rather than rewarding potential turnaround stories. The discount reflects the market's assessment of near-term earnings risk. Only a sustained return to positive EBITDA and stable revenue growth over at least two quarters could shift this market view.
Break down EVT.DE's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.